Acelrx announces an investigator-initiated study of dsuvia® in patients taking buprenorphine who require a surgical procedure

Redwood city, calif., april 8, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study at montefiore medical center evaluating the perioperative use of dsuvia (sufentanil sublingual tablet 30 mcg) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or for chronic pain management.
ACRX Ratings Summary
ACRX Quant Ranking